SynthesisPloS one2022
Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Pooled it
- Meta-analysis and moderator analysis of the seroprevalence of hepatitis E in South-Eastern Asia.Scientific reports · 2023Pooled it
- A One Health Approach to Hepatitis E Virus in Venezuela: Low Seroprevalence in Humans and First Genomic Evidence of Hepatitis E Virus Genotype 3 in a Domestic Swine.Microorganisms · 2026Article
- Hepatitis E Virus Infection in Patients With Chronic Liver Diseases: A Latin American Multicenter Study.The Journal of infectious diseases · 2026Article
- Seroprevalence and determinants of hepatitis E virus infection among people living with HIV in Chiang Mai, Thailand: a cross-sectional analysis.Scientific reports · 2026Article
- Hepatitis E Virus Infection in Brazil: A Scoping Review of Epidemiological Features.Pathogens (Basel, Switzerland) · 2025Article
- A Survey of Hepatitis B Virus and Hepatitis E Virus at the Human-Wildlife Interface in the Peruvian Amazon.Microorganisms · 2024Article
- Article
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Review
- The burden of hepatitis E virus infection among Ghanaian pregnant women.Frontiers in public health · 2024Article
- Epidemiology of HEV Infection in Blood Donors in Southern Switzerland.Microorganisms · 2023Article
- Age and Gender Trends in the Prevalence of Markers for Hepatitis E Virus Exposure in the Heterogeneous Bulgarian Population.Life (Basel, Switzerland) · 2023Article
- Review
- Seroprevalence of Hepatitis E virus in children and adolescents living in urban Bogotá: An explorative cross-sectional study.Frontiers in public health · 2023Article
- Exploring hepatitis E virus seroprevalence and associated risk factors among the human population in Tandil, Buenos Aires, Argentina.Frontiers in public health · 2023Article
- Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis E virus (HEV) infection is responsible for inflammatory liver disease and can cause severe health problems. Because the seroprevalence of HEV varies within different population groups and between regions of the continent, we conducted a systematic review on the topic in order to provide evidence for targeted prevention strategies.
methodsWe performed a systematic review in PubMed, SCIELO, LILACS, EBSCO, and Cochrane Library and included reports up to 25 May 2021 (PROSPERO registration number: CRD42020173934). We assessed the risk of bias, publication bias, and heterogeneity between studies and conducted a random-effect meta-analysis for proportions using a (binomial-normal) generalized linear mixed model (GLMM) fitted by Maximum Likelihood (ML). We also reported other characteristics like genotype and risk factors.
resultsOf 1212 identified records, 142 fulfilled the inclusion criteria and were included in the qualitative analysis and 132 in the quantitative analysis. Our random-effects GLMM pooled overall estimate for past infection (IgG) was 7.7% (95% CI 6.4%-9.2%) with high heterogeneity (I2 = 97%). We found higher seroprevalence in certain population groups, for example in people with pig related exposure for IgG (ranges from 6.2%-28% and pooled estimate of 13.8%, 95% CI: 7.6%-23.6%), or with diagnosed or suspected acute viral hepatitis for IgM (ranges from 0.3%-23.9% and pooled estimate of 5.5%, 95% CI: 2.0%-14.1%). Increasing age, contact with pigs and meat products, and low socioeconomic conditions are the main risk factors for HEV infection. Genotype 1 and 3 were documented across the region.
conclusionHEV seroprevalence estimates demonstrated high variability within the Americas. There are population groups with higher seroprevalence and reported risk factors for HEV infection that need to be prioritized for further research. Due to human transmission and zoonotic infections in the region, preventive strategies should include water sanitation, occupational health, and food safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.